Why would a CDH6 mAb ADC conjugated to a novel membrane permeable topoisomerase have safety issues?

A similar ADC HKT288 that used a DM4 payload with anti-CDH6 monoclonal was discontinued over inflammatory and neurological adverse events. Would the adverse events be tied to targeting CDH6 or to...

13 December 2021 9,334 0 View